The Cooper Companies, Inc. with ticker code (COO) have now 12 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 431 and 345 with the average target price sitting at $404.75. Given that the stocks previous close was at $383.43 and the analysts are correct then there would likely be a percentage uptick in value of 5.6%. There is a 50 day moving average of $375.27 and the 200 day MA is $334.34. The company has a market capitalization of 18.69B. The stock price is currently at: 377.42 USD
The potential market cap would be $19,724,236,152 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 65.18, revenue per share of 69.52 and a 2.62% return on assets.
The Cooper Companies, Inc. is a global medical device company. The Company operates through two segments: CooperVision and CooperSurgical. CooperVision segment is engaged in developing, manufacturing and marketing a range of products for contact lens wearers, featuring advanced materials and optics. CooperVision segment designs its products to solve vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigue, with a broad collection of spherical, toric and multifocal contact lenses. CooperSurgical segment focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women’s health and fertility. CooperSurgical segment supplies the family health care market with a diversified portfolio of products and services. Its office and surgical offerings include products that facilitate surgical and non-surgical procedures that are commonly performed primarily by obstetricians and gynecologists.
